Myelodysplastic Syndrome
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
News
FDA grants drug orphan designation for AML, MDS
The US Food and Drug Administration (FDA) has granted orphan drug designation to AMV564, a CD33/CD3 bispecific antibody, for the treatment of...
News
Rigosertib produces better OS in MDS than tAML
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from...
News
Generic azacitidine approved in Canada
Health Canada has approved Dr.
News
FDA approves first Erdheim-Chester disease treatment
Vemurafenib is now approved to treat ECD patients with the BRAF V600 mutation.
News
Drug receives fast track designation for lower-risk MDS
The US Food and Drug Administration (FDA) has granted fast track designation to the telomerase inhibitor imetelstat. The designation is for...
News
ATLG fights GVHD but reduces PFS, OS
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival...
News
Drug receives orphan designation for treatment of MDS
The European Commission has granted orphan designation to asunercept (APG101) for the treatment of myelodysplastic syndromes (MDS). Asunercept is...
News
Mutations impact outcomes in AML, MDS
Researchers say they have identified genetic mutations that can significantly affect treatment outcomes in patients with acute myeloid leukemia (...
News
FDA grants RMAT designation to HSCT adjunct
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATIR101™, which is intended to...
Conference Coverage
Antibody shows early promise in AML/MDS trial
MADRID—Interim results of a phase 1 study suggest flotetuzumab, a CD123 and CD3 bispecific antibody, may be a feasible treatment option for...